Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124
Q4 FY22 results · Jan–Mar 2022
Dr. Reddy's Laboratories reported revenue from operations of ₹5,474.90 crore (up 14.8% from Q4 FY21) and net profit of ₹97.00 crore (down 82.6% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 5,474.90 | 4,768.20 | +14.8% | 5,338.30 | +2.6% |
| Other income | 121.90 | 82.60 | +47.6% | 55.80 | +118.5% |
| Total income | 5,596.80 | 4,850.80 | +15.4% | 5,394.10 | +3.8% |
| Profit before share of associates & JVs and tax | 248.40 | 797.30 | −68.8% | 955.70 | −74.0% |
| Share of profit/(loss) of associates & JVs | 10.50 | 17.90 | 18.50 | ||
| Net profit for the period | 97.00 | 557.30 | −82.6% | 709.30 | −86.3% |
| EPS, basic (₹) | 5.84 | 33.61 | −82.6% | 42.75 | −86.3% |
| Net margin (%) | 1.8 | 11.7 | 13.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,668.70 | 3,350.70 | +9.5% | 3,479.60 | +5.4% |
| Other income | 114.70 | 81.60 | +40.6% | 63.00 | +82.1% |
| Total income | 3,783.40 | 3,432.30 | +10.2% | 3,542.60 | +6.8% |
| Profit before tax | 566.70 | 456.90 | +24.0% | 463.90 | +22.2% |
| Net profit for the period | 419.70 | 311.50 | +34.7% | 341.10 | +23.0% |
| EPS, basic (₹) | 25.29 | 18.78 | +34.7% | 20.55 | +23.1% |
| Net margin (%) | 11.4 | 9.3 | 9.8 |
Consolidated
- Filed with BSE
- 19 May 2022, 18:15 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 May 2022, 18:15 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE